|
|
Profile
|
Delegates :
Kohei Ishihama |
|
Incorporated :
January 22 , 2021 |
Paid in Capital :
1500 Million yen |
Employees :
7 人 |
Address :
4-1 Kyudai-Shinmachi Nishi-ku, Fukuoka-shi, Fukuoka FUKUOKA
〒819-0388
|
TEL/FAX :
/ |
URL：
https://www.novigopharma.co.jp/en |
Attachment :
|
Mission/Background :
We specialize in next-generation drug delivery system (DDS) technologies using its proprietary lipid nanoparticle technology. With a focus on reducing patient burden, it is developing transdermal drug delivery for skin absorption and intracellular drug delivery. We applie its DDS expertise to cosmetics, enhance the absorption of poorly absorbable active ingredients. Through these innovations, the company aims to advance both pharmaceuticals and cosmetics, improving health and quality of life. |
|
Technology & Business
|
The company's ILB technology leverages specialized lipids to form nanoparticles, enabling efficient intracellular delivery of active ingredients. It facilitates the introduction of nucleic acids and protein-based drugs, supporting cell functionalization in cellular therapy research. Additionally, ILB technology allows for the efficient post-loading of active ingredients into extracellular vesicles (EVs), including exosomes, with lower toxicity and easier preparation compared to viral and other non-viral methods. EVs serve as a promising drug delivery system, reaching target organs beyond the capabilities of conventional synthetic systems. The company is actively advancing research in EV-based drug delivery for pharmaceutical applications. Furthermore, its technology enhances the transdermal absorption of water-soluble compounds. This innovation has already been adopted by major cosmetics companies, leading to the commercialization of multiple products.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
ILB Technology
|
Discovery
|
A technology enabling the safe and efficient delivery of nucleic acids, proteins, and bioactive molecules for cell therapy.
|
This technology is provided on a closed basis. Contact us if you are interested in comparing it with existing approaches.
|
H-EV Technology
|
Discovery
|
A non-invasive Post-Loading technology of active compounds into extracellular vesicles (EVs), including exosomes.
|
Collaboration with companies utilizing EVs as natural DDS carriers for targeted delivery to the brain and other organs
|
S/O Patch
|
Discovery
|
A long-acting transdermal patch technology that enhances drug absorption by nanoparticulating water-soluble drugs.
|
Collaboration with companies looking to explore transdermal absorption as a delivery route for existing or new APIs.
|
S/O Customization Service
|
Launched
|
A service that improves the absorption of water-soluble active ingredients by nanoparticulation.
|
Contract research for companies developing high-permeability cosmetic products for their own brand or clinic sales.
|
|
|
|
|
|
Alliance strategy
|
To accelerate proof-of-concept studies and joint research utilizing our DDS technology, we aim to expedite the practical application of EV-based formulations. While there are no restrictions on target organs, we are particularly looking for partners interested in developing EV-DDS treatments in the field of neurological disorders.
|
|
|